Page 1

ΔΕΛΤΙΟ ΤΥΠΟΥ H1 2026 Financial Results ✓ Lavipharm - Paiania , 17 September 2026 – The Lavipharm Group , during H1 2026 , reported a significant increase in consolidated sales prior to clawback and rebate of 24.1 % , while EBITDA from continuing operations increased by 5.2 % . Specifically , consolidated sales from continuing operations amounted to € 38.5 million , compared to € 31.0 million in the corresponding period of 2025 , recording an increase of 24.1 % . In particular , sales abroad increased by 35 % , sales of prescription medicines in the domestic market increased by 23 % , while OTC sales increased by 3 % . Consolidated sales , after the deduction of clawback and rebates , amounted to € 34.4 million , compared to € 26.7 million in the corresponding period of 2025 , representing an increase of 28.9 % . Total adjusted EBITDA stood at € 7.1 million , compared to € 7.7 million in H1 2025 , representing a decrease of 7.7 % , due to the extraordinary income of € 0.9 million from the sale of Pharma Plus , which took place in H1 2025 . Consolidated earnings after taxes amounted to € 2.4 million , compared to € 2.6 million in H1 2025. This decrease is also attributable to the income from the sale of Pharma Plus recognized in H1 2025. It is worth noting that , excluding this specific income , net earnings from continuing operations increased by 41.3 % compared to H1 2025 . The Group's net debt , as at 30/6/2026 , stood at € 37.7 million , representing an increase compared to 31/12/2025 due to the bank financing of the DUROGESIC® acquisition . Mr. Vassilis Baloumis , Chief Financial Officer of Lavipharm , stated : " The Group's upward trajectory will continue at a faster pace in H2 2026. Sales for the period are expected to be significantly higher than those of the first half , both in the domestic market and abroad , where the pace of order fulfillment will accelerate particularly towards the end of the year . It is worth noting that this estimate does not include DUROGESIC® , whose commercial distribution is expected to begin in early October , as the licensing procedures have already been completed in the countries of greatest commercial interest . Finally , it should be noted that the H1 figures include approximately € 300 thousand in payroll - related expenses incurred in preparation for the commercialization of this specific product . " ΔΕΛΤΙΟ ΤΥΠΟΥ ΔΕΛΤΙΟ ΤΥΠΟΥ ### For further information : Investor Relations Vassilis Baloumis Tel . +30 210 6691 121 ir@lavipharm.com Corporate Communications Vivienne Thomas Tel . +30 210 6691 404 vthomas@lavipharm.com ΩΤΕΡΙΚΟ ΟΔΟΣ ΑΓΙΑΣ ΜΑΡΙΝΑΣ , Τ.Θ. 59 , 190 02 ΠΑΙΑΝΙΑ ΑΤΤΙΚΗΣ , ΤΗΛ .: 210 6691 000 , FAX : 210 6691 208 , www.lavipharm.gr